Skip to main content
Back
RIGL logo

Rigel Pharmaceuticals, Inc.

Data quality: 100%
RIGL
NASDAQ Healthcare Biotechnology
CEO: Raul R. Rodriguez Employees: 162 IPO: Nov 29, 2000
Price
$27.50
Change
▲ $0.46
1.70%
Mkt Cap
508.01M
Day Range
$27.35 $28.23
52-Week Range
$15.50 $52.24
Volume
239,451
50D / 200D Avg
$31.80
$32.98
Prev Close
$27.04

Quick Summary

Key Takeaways

Revenue grew 18.50% annually over 5 years — strong growth
Earnings grew 1999.08% over the past year
ROE of 185.94% indicates high profitability
Net margin of 124.72% shows strong profitability
Debt/Equity of 0.14 — conservative balance sheet
Generating 75.66M in free cash flow

Growth

Revenue Growth (5Y)
18.50%
Above sector avg (9.60%)
Revenue (1Y)64.15%
Earnings (1Y)1999.08%
FCF Growth (3Y)N/A

Quality

Return on Equity
185.94%
Above sector avg (3.61%)
ROIC21.16%
Net Margin124.72%
Op. Margin42.63%

Safety

Debt / Equity
0.14
Below sector avg (0.23)
Current Ratio2.42
Interest Coverage17.14

Valuation

P/E Ratio
1.38
Above sector avg (0.23)
Forward P/EN/A
P/B Ratio1.30
EV/EBITDA4.15
Dividend Yield0.00%

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (638 peers)

Metric Stock Sector Median
P/E 1.4 0.2
P/B 1.3 2.9
ROE % 185.9 3.6
Net Margin % 124.7 3.9
Rev Growth 5Y % 18.5 9.6
D/E 0.1 0.2

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64.15% Revenue Growth (3Y) 58.67%
Earnings Growth (1Y) 1999.08% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 18.50% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 294.28M Net Income (TTM) 367.02M
ROE 185.94% ROA 71.46%
Gross Margin 93.33% Operating Margin 42.63%
Net Margin 124.72% Free Cash Flow (TTM) 75.66M
ROIC 21.16% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.14 Current Ratio 2.42
Interest Coverage 17.14
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1.38 Forward P/E N/A
P/B Ratio 1.30 P/S Ratio 1.73
PEG Ratio 0.00 Forward PEG N/A
EV/EBITDA 4.15 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 14.89%
Market Cap 508.01M Enterprise Value 520.73M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 294.28M 179.28M 116.88M 120.24M 149.24M
Net Income 367.02M 17.49M -25.09M -58.57M -17.91M
EPS (Diluted) 19.48 0.99 -1.44 -3.40 -1.10
Gross Profit 274.66M 160.63M 109.77M 118.49M 148.15M
Operating Income 125.47M 24.19M -20.49M -55.55M -12.50M
EBITDA 127.88M 28.51M -16.98M -53.87M -11.29M
R&D Expenses 33.30M 23.38M 24.52M 60.27M 65.24M
SG&A Expenses 115.90M 113.06M 105.74M 112.45M 91.89M
D&A 2.42M 2.23M 1.24M 998,000.0 1.16M
Interest Expense 7.32M 7.92M 6.87M 3.71M 4.86M
Income Tax -245.20M 881,000.0 0.0 0.0 605,000.0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 513.59M 163.98M 117.23M 134.28M 167.33M
Total Liabilities 122.11M 160.69M 145.87M 147.90M 136.95M
Shareholders' Equity 391.48M 3.29M -28.64M -13.62M 30.37M
Total Debt 53.30M 59.97M 60.58M 41.55M 30.57M
Cash & Equivalents 40.58M 56.75M 32.79M 24.46M 18.89M
Current Assets 240.17M 135.10M 99.27M 115.90M 154.47M
Current Liabilities 99.24M 63.30M 53.27M 65.21M 63.55M

Strategy Scores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#6 of 223
80
Custom Growth Investing (Philip Fisher)
#14 of 153
89
Custom Value Investing (Warren Buffett)
#62 of 200
45
Custom Full Throttle
#113 of 141
29
Custom Lower Risk
#22 of 136
57

Recent Activity

Entered Capital Light Compounder
Apr 2, 2026
Entered Growth Investing (Philip Fisher)
Apr 2, 2026
Entered Value Investing (Warren Buffett)
Apr 2, 2026
Entered Full Throttle
Apr 2, 2026
Entered Lower Risk
Apr 2, 2026